Long term recombinant interferon alpha treatment in MS with special emphasis to side effects
Long term recombinant interferon alpha treatment in MS with special emphasis to side effects
复制标题
多发性硬化症的长期重组干扰素α治疗，特别强调副作用
DOI：
10.1177/135245859600100617
复制
发表时间：
1996
期刊：
影响因子：
--
通讯作者：
B. Bergamasco
中科院分区：
文献类型：
--
作者：
L. Durelli;M. Bongioanni;B. Ferrero;D. Imperiale;E. Verdun;A. Oggero;E. Gentile;G. Bradač;M. Bergui;L. Bergamini;B. Bergamasco
20 名临床明确的复发缓解型 (RR) 多发性硬化症患者每隔一天接受 9 MIU 肌内重组干扰素 α-2a (rIFNA)（Rof eron-A，罗氏）（n=12）或安慰剂（n=8）治疗，为期 6 个月，并在停止治疗后进一步随访 6 个月。治疗期间下降，停止治疗后恢复到与基线和安慰剂相似的值，因此似乎需要 rIFNA 长期治疗以维持药物疗效。还对这 20 名患者以及另外 25 名 RR MS 患者的副作用进行了为期一年多的监测。除了 1 型干扰素治疗的典型副作用（发烧、疲劳、抑郁、淋巴细胞减少、肝酶升高）外，30% 的患者出现血清自身抗体（60% 为抗核自身抗体，80% 为抗甲状腺自身抗体）。两名患者停止了 rIFNA 治疗，其中一名患者因抗甲状腺自身抗体和甲状腺功能减退而停止，另一名患者因抗核自身抗体和 ALT 升高五倍而停止。在长期 1 型干扰素治疗之前和同时，必须仔细监测血清自身抗体以及甲状腺或肝脏损伤的体征。
Twenty relapsing-remitting (RR) clinically definite MS patients were treated with 9 MIU intramuscular recombinant interferon alpha-2a (rIFNA) (Rof eron-A, Roche) (n=12) or placebo (n=8) every other day for 6 months and followed up for a further 6 months after stopping treatment Numbers of active lesions at MRI and of patients with clinical-MRI signs of disease activity and lymphocyte interferon gamma production, which were decreased during treatment, returned to values similar to baseline and placebos after stopping treatment rIFNA chronic therapy seems therefore needed in order to maintain drug efficacy. Side effect prof ile was monitored, too, for over 1 year in the same 20 patients plus 25 additional RR MS patients. Besides the typical side effects of type 1 interferon therapy (fever, fatigue, depression, lymphopenia, hepatic enzyme elevation), occurrence of serum autoAbs was noted in 30% patients (in 60% antinuclear and in 80% antithyroid autoAbs). In two patients rIFNA treatment was stopped, in one case for antithyroid autoAbs and hypothyroidism, in the other for antinuclear autoAbs and a five-fold increase of ALT. A careful monitoring of serum autoAbs and of signs of thyroid or liver damage must always precede and accompany longterm type 1 IFN therapy.
影响因子：
2.7
作者：
Benedict, Ralph H. B.;Bobholz, Julie H.
通讯作者：
Bobholz, Julie H.